When challenging a patent in an inter partes review (“IPR”), petitioners are limited to arguing that the patent is anticipated or obvious based on existing patents and printed publications. According to 35 U.S.C. § 315(e)(1) and (2), a petitioner in an IPR that results in a final written decision (FWD) may not raise in the USPTO or a civil action or an ITC proceeding “any ground that the petitioner raised or reasonably could have raised during that inter partes review.” But, what if a prior art physical product is cumulative of a printed publication raised in an IPR? Courts have been asked to consider whether estoppel attaches to physical products that are described in patents or printed publications. Petitioners need to be aware of this po...
Increasingly, accused infringers challenge a patent’s validity in two different forums: in litigatio...
Article I of the Constitution\u27 expressly provides Congress with the authority to grant inventors ...
The recent Supreme Court decision in MedImmune v. Genentech, resolved a jurisdictional question whil...
When challenging a patent in an inter partes review (“IPR”), petitioners are limited to arguing that...
It is becoming increasingly apparent that inter partes review (“IPR”) petitioner estoppel after the ...
When Congress implemented inter partes review (IPR) and other patent post-grant proceedings through ...
Prior art in patent law defines the set of materials that the United States Patent and Trademark Off...
Marking is the act of placing a patent number on a product or its packaging. The doctrine of marking...
The inter partes review (IPR) is an administrative procedure conducted by the Patent Trial and Appea...
The subject patent in the case of Scripps Clinic & Research Foundation v. Genentech, Inc.I was a...
This is a brief of 72 IP professors opposing the claim in Oil States that the IPR procedure is uncon...
The recent passing of the America Invents Act came with the creation of three brand new forms of pos...
The high profile cases Bilski v. Kappos and Association for Molecular Pathology v. United States Pat...
Patent cases use a preponderance of the evidence standard of proof, unless the validity of a paten...
The Supreme Court’s 2017 ruling in Impression Products v. Lexmark clearly came as an unwelcome, thou...
Increasingly, accused infringers challenge a patent’s validity in two different forums: in litigatio...
Article I of the Constitution\u27 expressly provides Congress with the authority to grant inventors ...
The recent Supreme Court decision in MedImmune v. Genentech, resolved a jurisdictional question whil...
When challenging a patent in an inter partes review (“IPR”), petitioners are limited to arguing that...
It is becoming increasingly apparent that inter partes review (“IPR”) petitioner estoppel after the ...
When Congress implemented inter partes review (IPR) and other patent post-grant proceedings through ...
Prior art in patent law defines the set of materials that the United States Patent and Trademark Off...
Marking is the act of placing a patent number on a product or its packaging. The doctrine of marking...
The inter partes review (IPR) is an administrative procedure conducted by the Patent Trial and Appea...
The subject patent in the case of Scripps Clinic & Research Foundation v. Genentech, Inc.I was a...
This is a brief of 72 IP professors opposing the claim in Oil States that the IPR procedure is uncon...
The recent passing of the America Invents Act came with the creation of three brand new forms of pos...
The high profile cases Bilski v. Kappos and Association for Molecular Pathology v. United States Pat...
Patent cases use a preponderance of the evidence standard of proof, unless the validity of a paten...
The Supreme Court’s 2017 ruling in Impression Products v. Lexmark clearly came as an unwelcome, thou...
Increasingly, accused infringers challenge a patent’s validity in two different forums: in litigatio...
Article I of the Constitution\u27 expressly provides Congress with the authority to grant inventors ...
The recent Supreme Court decision in MedImmune v. Genentech, resolved a jurisdictional question whil...